Description
PURCHASE ORDER FOR CITALOPRAM
First action · last action
2017-04-06 · 2017-04-06
Transactions
1
First transaction's obligation
$88,200
Base + all options value (sum of deltas)
$88,200
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
VA797P16A0005
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-04-06+$88,200= $88,200
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-04-06 | +$88,200 | $88,200 | PURCHASE ORDER FOR CITALOPRAM |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI FYZXNHSQTMG8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24226N0564 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $5,337,256 | FY2026 |
| 36C25926F0197 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $1,844,059 | FY2026 |
| 36C26026F0261 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $918,831 | FY2026 |
| 36E79726D0021 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26026F0169 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $712,808 | FY2026 |
| 36C24426N0400 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $1,487,248 | FY2026 |
Other recipients under 6505 from NAC PHARMACEUTICALS 36P797 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA797P17J0052 | MYLAN PHARMACEUTICALS INC | NAC PHARMACEUTICALS 36P797 | $6,169 | FY2017 |
| VA797P17J0051 | MYLAN PHARMACEUTICALS INC | NAC PHARMACEUTICALS 36P797 | $17,881 | FY2017 |
| VA797P17J0050 | MYLAN PHARMACEUTICALS INC | NAC PHARMACEUTICALS 36P797 | $72,904 | FY2017 |
| VA797P17J0048 | KREMERS URBAN PHARMACEUTICALS INC. | NAC PHARMACEUTICALS 36P797 | $1,225,936 | FY2017 |
| VA797P17J0054 | EXCELLIUM PHARMACEUTICAL INC. | NAC PHARMACEUTICALS 36P797 | $48,519 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA797P17J0053_3600_VA797P16A0005_3600 · retrieved 2026-09-26.